Skip to main content

Table 1 Clinical and laboratory (BNP level) characteristics of normal controls and PAH patients

From: Deformation pattern and predictive value of right ventricular longitudinal strain in children with pulmonary arterial hypertension

Variable Control (n = 21) PAH patients (n = 25) P
Age (y) 10.97 ± 3.48 11.07 ± 3.44 0.821
Male (%) 10 (47.61 %) 11 (44.00 %) 1.000
H (cm) 147.50 (133.25,156.75) 136 (119.00,147.00) 0.081
W (kg) 42.15 ± 18.15 29.95 ± 12.07 0.010
BSA (m2) 1.29 ± 0.36 1.05 ± 0.27 0.012
BMI (m/kg2) 18.31 ± 3.48 15.53 ± 2.97 0.016
6MWD (m) 480.35 ± 55.03 413.66 ± 75.31 0.001
 SpO2 before 6MWT (%) 98.00 (95.20,98.90) 85.71 ± 9.52 0.0001
 SpO2 after 6MWT (%) 98.00 (97.00,99.00) 75.80 ± 15.59 0.0001
 HR before 6MWT (bpm) 86.15 ± 11.79 98.90 ± 14.38 0.190
 HR after 6MWT (bpm) 109.20 ± 14.84 114.90 ± 16.09 0.246
WHO Functional class
1/2/3/4
NA 0/15/9/1
0/60 %/36 %/4 %
 
BNP level (pg/ml) 9.00 (10.48,16.34) 25.85 (27.98,80.28) 0.005
PAH type    
 Idiopathic NA 5 (20 %) NA
 Ventricular septal defect NA 12 (48 %) NA
 Atrioventricular septal defect NA 5 (20 %) NA
 Truncus arteriosus communis NA 3 (12 %) NA
Medication no(%)    
 Sildenafil NA 5 (20 %) NA
 Bosentan NA 13 (52 %) NA
 Combination (Sildenafil + Bosentan) NA 7 (28 %) NA
  1. Data are presented as means ± SD or median (25th, 75th percentiles) or as numbers (percentages)
  2. BMI body mass index, BNP brain natriuretic peptide, BSA body surface area, H height, HR heart rate, PAH pulmonary arterial hypertension, SpO 2 oxygen saturation, W weight, 6MWD 6-min walk distance